Global EditionASIA 中文雙語Fran?ais
    Opinion
    Home / Opinion / Op-Ed Contributors

    UK's vaccine gamble carries serious risks

    By Sanjeev Krishna/Yolanda Augustin | China Daily | Updated: 2021-01-30 09:16
    Share
    Share - WeChat
    A vial and sryinge are seen in front of a displayed AstraZeneca logo in this illustration taken on Jan 11, 2021. [Photo/Agencies]

    The British have often taken pride in dubious achievements, from the "victorious" retreat from Dunkirk during World War II to the bare-minimum Brexit agreement recently reached with the European Union.

    The development of a COVID-19 vaccine on British soil, however, was a genuine triumph. And yet, by delaying the delivery of second vaccine doses, the government is set to undercut this feat-and its overall pandemic-containment strategy.

    The manufacturers of all three vaccines so far approved in the United Kingdom-the homegrown AstraZeneca/University of Oxford DNA vaccine, and the Pfizer/BioNTech and Moderna mRNA vaccines-recommend delivering the second dose three-four weeks after the first. And yet the UK government has decided to leave a 12-week gap between doses.

    This decision's defenders note that the first dose provides most of the initial protection from clinical disease, whereas the second dose is likely to be more important for duration of protection. Given the urgency of the public health crisis-and the possibility of supply delays or shortages in the future-spreading limited doses more widely now seems like a better bet than fully inoculating a smaller group.

    But there are major potential risks. For starters, some doctors have been instructed to cancel existing appointments for second doses. Before receiving the first dose, those patients would have consented to receive two doses on a particular schedule. Changing that schedule would thus amount to an ethical violation, unless patients are given the opportunity to choose whether to consent to the new schedule or stick to the old one.

    For this choice to be credible, all relevant information about the new vaccine schedule would need to be disclosed. Yet information about the 12-week schedule is sorely lacking. In fact, claims that the delay will not reduce efficacy, and may even increase the immunological response (antibody levels), are based on a post hoc analysis of results from trials of just one vaccine.

    It started with a mistake: a small subset of volunteers in the AstraZeneca-Oxford vaccine trials was inadvertently given a smaller first dose. The second dose was then delayed, presumably because the mistake had to be investigated.

    So, a new analysis was carried out. It revealed the dosing mistake was a breakthrough: a smaller initial dose actually made the vaccine more effective. Then a second analysis suggested the delayed second dose also played a role in boosting efficacy. There were no additional clinical trials designed to test the extended dosing schedule, as would normally be expected.

    On the contrary, British medical officers decided that what is good for the goose is good for the Pfizer/BioNTech and Moderna ganders. But the AstraZeneca-Oxford vaccine works differently from the others; and the latter two are the result of testing processes that proved them to be safe and highly effective. How can the findings of a post hoc analysis of a flawed trial of a completely different-and less effective-vaccine be regarded as a convincing reason to stray from a proven formula? Pfizer, not surprisingly, advises against abandoning its recommended schedule.

    One might make the untested but well-founded argument that we understand vaccine immunology well enough to be able to say that one immune response is much like another. Even mixing vaccines is sometimes acceptable.

    But we do not understand the biology and immunology of SARS-CoV-2 (the virus that causes COVID-19) well at all. After thorough investigation, some empirically derived interventions have already proved to be inappropriate. For example, rigorous study has debunked the claim that former US president Donald Trump's one-time darling, hydroxychloroquine, is useful in combating COVID-19. In fact, the malaria medication may harm patients.

    What harm could the delayed second vaccine dose cause? If patients' immune responses fade between doses, they will be left vulnerable to infection. This risk, however, could be counterbalanced by the increased number of individuals vaccinated, especially in high-transmission areas.

    A more profound threat lies in the potential emergence of virus variants on which existing vaccines don't work. Once a large percentage of the population is vaccinated, immune pressure could accelerate the emergence of such variants by selecting for "escape mutants" (which do not confer antibody resistance).

    This could happen regardless of what vaccine schedule is used, but the 12-week timeline intensifies the risk. After all, as immunity decreases, the chances of selecting for escape mutants may rise, not least because the virus is likely to infect people with incomplete vaccine responses. Just as completing a round of antibiotics is essential to minimize the emergence of resistant bacteria, delivering maximal immunity rapidly (using the conventional dosing schedule) could help to preserve vaccine efficacy.

    With the UK government having already implemented the scheduling change, there is little we can do now but test the assumptions on which it rests. How much immunity does one vaccine dose provide 84 days later? Do both vaccine types generate similar degrees of immunity? Is the risk of SARS-CoV-2 infection higher between the four-week and 12-week marks? Are new viral variants with escape mutations emerging in vaccine recipients?

    During the pandemic, the UK led the way in studying pharmaceutical interventions, with well-designed randomized controlled studies enabling vast improvements in patient care globally. There is no excuse to abandon this evidence-oriented approach now.

    If the UK will not delay implementation of its vaccine-dosing decision, it should at least launch rigorous studies to assess the risks. The country has already produced a more transmissible variant of the novel coronavirus. It should not compound the threat to public health with potentially lethal policy mistakes.

    Sanjeev Krishna is a professor of Molecular Parasitology and Medicine at St George's, University of London's Centre for Infection, and Yolanda Augustin is a doctor at St George's, University of London.

    Project Syndicate

    The views don't necessarily reflect those of China Daily.

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    精品久久久无码人妻中文字幕| 99久久无码一区人妻| 国产在线无码视频一区二区三区| 日韩欧群交P片内射中文| 久久午夜伦鲁片免费无码| 亚洲不卡无码av中文字幕| 亚洲av无码专区在线观看下载| 亚洲Aⅴ无码专区在线观看q| 亚洲乱码中文字幕综合234| 中文字幕亚洲男人的天堂网络 | h无码动漫在线观看| 亚洲精品无码专区久久久 | 久久五月精品中文字幕| 国产精品 中文字幕 亚洲 欧美 | 无码精品一区二区三区在线| 最近免费中文字幕中文高清| 7777久久亚洲中文字幕| 午夜亚洲av永久无码精品| 国产精品亚洲专区无码WEB| 日韩乱码人妻无码中文字幕久久 | 无码国产精品一区二区免费式影视| 欧美乱人伦中文字幕在线| 久久人妻少妇嫩草AV无码蜜桃 | 久久亚洲av无码精品浪潮| 精品无码日韩一区二区三区不卡| 人妻AV中出无码内射| 一夲道DVD高清无码| 中文无码不卡的岛国片| 中文字幕日韩精品无码内射| 日韩欧美一区二区三区中文精品 | 最近2022中文字幕免费视频| 中文字幕无码av激情不卡久久| 日韩A无码AV一区二区三区| 人妻无码精品久久亚瑟影视| 日韩精品无码免费视频| 日产无码1区2区在线观看| 中中文字幕亚洲无线码| 中文字幕亚洲欧美日韩在线不卡| 久久人妻无码中文字幕| 最近免费中文字幕大全免费版视频| 天堂资源8中文最新版|